Mesenchymal Stem Cells for Cardiac Regeneration: Translation to Bedside Reality
Cardiovascular disease (CVD) is the leading cause of death worldwide. According to the World Health Organization (WHO), an estimate of 17.3 million people died from CVDs in 2008 and by 2030, the number of deaths is estimated to reach almost 23.6 million. Despite the development of a variety of treat...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2012/646038 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849694508123422720 |
|---|---|
| author | Mohammad T. Elnakish Fatemat Hassan Duaa Dakhlallah Clay B. Marsh Ibrahim A. Alhaider Mahmood Khan |
| author_facet | Mohammad T. Elnakish Fatemat Hassan Duaa Dakhlallah Clay B. Marsh Ibrahim A. Alhaider Mahmood Khan |
| author_sort | Mohammad T. Elnakish |
| collection | DOAJ |
| description | Cardiovascular disease (CVD) is the leading cause of death worldwide. According to the World Health Organization (WHO), an estimate of 17.3 million people died from CVDs in 2008 and by 2030, the number of deaths is estimated to reach almost 23.6 million. Despite the development of a variety of treatment options, heart failure management has failed to inhibit myocardial scar formation and replace the lost cardiomyocyte mass with new functional contractile cells. This shortage is complicated by the limited ability of the heart for self-regeneration. Accordingly, novel management approaches have been introduced into the field of cardiovascular research, leading to the evolution of gene- and cell-based therapies. Stem cell-based therapy (aka, cardiomyoplasty) is a rapidly growing alternative for regenerating the damaged myocardium and attenuating ischemic heart disease. However, the optimal cell type to achieve this goal has not been established yet, even after a decade of cardiovascular stem cell research. Mesenchymal stem cells (MSCs) in particular have been extensively investigated as a potential therapeutic approach for cardiac regeneration, due to their distinctive characteristics. In this paper, we focus on the therapeutic applications of MSCs and their transition from the experimental benchside to the clinical bedside. |
| format | Article |
| id | doaj-art-fa39c3cb7f1d4dfca3b6dc51bef05a36 |
| institution | DOAJ |
| issn | 1687-966X 1687-9678 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-fa39c3cb7f1d4dfca3b6dc51bef05a362025-08-20T03:20:03ZengWileyStem Cells International1687-966X1687-96782012-01-01201210.1155/2012/646038646038Mesenchymal Stem Cells for Cardiac Regeneration: Translation to Bedside RealityMohammad T. Elnakish0Fatemat Hassan1Duaa Dakhlallah2Clay B. Marsh3Ibrahim A. Alhaider4Mahmood Khan5Department of Physiology and Cell Biology, The Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University, Columbus, OH 43210, USADivision of Cardiovascular Medicine, Department of Internal Medicine, The Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University, Columbus, OH 43210, USADivision of Pulmonary and Critical Care, Department of Internal Medicine, The Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University, Columbus, OH 43210, USADivision of Pulmonary and Critical Care, Department of Internal Medicine, The Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University, Columbus, OH 43210, USADepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi ArabiaDivision of Cardiovascular Medicine, Department of Internal Medicine, The Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University, Columbus, OH 43210, USACardiovascular disease (CVD) is the leading cause of death worldwide. According to the World Health Organization (WHO), an estimate of 17.3 million people died from CVDs in 2008 and by 2030, the number of deaths is estimated to reach almost 23.6 million. Despite the development of a variety of treatment options, heart failure management has failed to inhibit myocardial scar formation and replace the lost cardiomyocyte mass with new functional contractile cells. This shortage is complicated by the limited ability of the heart for self-regeneration. Accordingly, novel management approaches have been introduced into the field of cardiovascular research, leading to the evolution of gene- and cell-based therapies. Stem cell-based therapy (aka, cardiomyoplasty) is a rapidly growing alternative for regenerating the damaged myocardium and attenuating ischemic heart disease. However, the optimal cell type to achieve this goal has not been established yet, even after a decade of cardiovascular stem cell research. Mesenchymal stem cells (MSCs) in particular have been extensively investigated as a potential therapeutic approach for cardiac regeneration, due to their distinctive characteristics. In this paper, we focus on the therapeutic applications of MSCs and their transition from the experimental benchside to the clinical bedside.http://dx.doi.org/10.1155/2012/646038 |
| spellingShingle | Mohammad T. Elnakish Fatemat Hassan Duaa Dakhlallah Clay B. Marsh Ibrahim A. Alhaider Mahmood Khan Mesenchymal Stem Cells for Cardiac Regeneration: Translation to Bedside Reality Stem Cells International |
| title | Mesenchymal Stem Cells for Cardiac Regeneration: Translation to Bedside Reality |
| title_full | Mesenchymal Stem Cells for Cardiac Regeneration: Translation to Bedside Reality |
| title_fullStr | Mesenchymal Stem Cells for Cardiac Regeneration: Translation to Bedside Reality |
| title_full_unstemmed | Mesenchymal Stem Cells for Cardiac Regeneration: Translation to Bedside Reality |
| title_short | Mesenchymal Stem Cells for Cardiac Regeneration: Translation to Bedside Reality |
| title_sort | mesenchymal stem cells for cardiac regeneration translation to bedside reality |
| url | http://dx.doi.org/10.1155/2012/646038 |
| work_keys_str_mv | AT mohammadtelnakish mesenchymalstemcellsforcardiacregenerationtranslationtobedsidereality AT fatemathassan mesenchymalstemcellsforcardiacregenerationtranslationtobedsidereality AT duaadakhlallah mesenchymalstemcellsforcardiacregenerationtranslationtobedsidereality AT claybmarsh mesenchymalstemcellsforcardiacregenerationtranslationtobedsidereality AT ibrahimaalhaider mesenchymalstemcellsforcardiacregenerationtranslationtobedsidereality AT mahmoodkhan mesenchymalstemcellsforcardiacregenerationtranslationtobedsidereality |